

# Niosomes: A Camouflaged Carrier for Drug Delivery System

Aftab Patel, Tejashri Kamble, Kare Deepak, Sonar Mayur, Kamble Sharad, Santosh Payghan

Department of Quality Assurance

Nootan College of Pharmacy, Kavathe Mahankal, Sangli, Maharashtra, India

**Abstract:** *The formation of vesicles as a tool to improve the drug delivery system. Niosomes are a system aimed at delivering drugs. Niosomes of non-ionic vesicles are highly affected by the hydration of nonionic syntactants, or unmixed cholesterol or other lipids. Niosomes promise a drug delivery and non-ionic vehicle, is less toxic and improves drug treatment index by inhibiting its action to target cells and play a key role in regulating nutrient release. Niosomes are preferred over liposomes because the former exhibit high chemical stability and economy. The application of vesicular (lipid vesicles and non-ionic surfactant vesicles) systems in cosmetics and for therapeutic purpose may offer several advantages. They improve the therapeutic performance of the drug molecules by delayed clearance from the circulation, protecting the drug from biological environment and restricting effects to target cells. This article focuses on the recent advances in niosomal drug delivery, potential advantages over other delivery systems, formulation methods, methods of characterization and the current research in the field of niosomes.*

**Keywords:** Niosomes, Proniosomes, Non-ionic surfactant, Cholesterol

## REFERENCES

- [1]. L. Tavano, L. Gentile, C. Oliviero Rossi, and R. Muzzalupo, "Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery," *Colloids and Surfaces B: Biointerfaces*, vol. 110, pp. 281–288, 2013.
- [2]. K. B. Bini, D. Akhilesh, P. Prabhakara, and K. Jv, "Development and characterization of non-ionic surfactant vesicles (niosomes) for oral delivery of lornoxicam," *International Journal of Drug Development and Research*, vol. 4, no. 3, pp. 147–154, 2012.
- [3]. Q. Li, Z. Li, W. Zeng et al., "Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection," *European Journal of Pharmaceutical Sciences*, vol. 62, pp. 115–123, 2014.
- [4]. Z. S. Bayindir, A. Besikci, and N. Yuksel, "Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats," *Turkish Journal of Medical Sciences*, vol. 45, no. 6, pp. 1403–1412, 2015.
- [5]. C. Marianecchi, F. Rinaldi, M. Mastriota et al., "Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models," *Journal of Controlled Release*, vol. 164, no. 1, pp. 17–25, 2012.
- [6]. S. K. Mehta and N. Jindal, "Tyloxapol niosomes as prospective drug delivery modle for antiretroviral drug nevirapine," *AAPS PharmSciTech*, vol. 16, no. 1, pp. 67–75, 2015.
- [7]. P. Arunothayanun, M.-S. Bernard, D. Q. M. Craig, I. F. Uchegbu, and A. T. Florence, "The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether," *International Journal of Pharmaceutics*, vol. 201, no. 1, pp. 7–14, 2000.
- [8]. A. Pardakhty, J. Varshosaz, and A. Rouholamini, "In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin," *International Journal of Pharmaceutics*, vol. 328, no. 2, pp. 130–141, 2007.
- [9]. M. Manconi, D. Valenti, C. Sinico, F. Lai, G. Loy, and A. M. Fadda, "Niosomes as carriers for tretinoin: II. Influence of vesicular incorporation on tretinoin photostability," *International Journal of Pharmaceutics*, vol. 260, no. 2, pp. 261–272, 2003.

- [10]. Z. S. Bayindir and N. Yuksel, "Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery," *Journal of Pharmaceutical Sciences*, vol. 99, no. 4, pp. 2049–2060, 2010.
- [11]. D. Paolino, D. Cosco, R. Muzzalupo, E. Trapasso, N. Picci, and M. Fresta, "Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer," *International Journal of Pharmaceutics*, vol. 353, no. 1-2, pp. 233–242, 2008.
- [12]. D. Paolino, R. Muzzalupo, A. Ricciardi, C. Celia, N. Picci, and M. Fresta, "In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery," *Biomedical Microdevices*, vol. 9, no. 4, pp. 421–433, 2007.
- [13]. T. Yoshioka, B. Sternberg, and A. T. Florence, "Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85)," *International Journal of Pharmaceutics*, vol. 105, no. 1, pp. 1–6, 1994.
- [14]. V. C. Okore, A. A. Attama, K. C. Ofokansi, C. O. Esimone, and E. B. Onuigbo, "Formulation and evaluation of niosomes," *Indian Journal of Pharmaceutical Sciences*, vol. 73, no. 3, pp. 323–328, 2011.
- [15]. D. Akhilesh, K. B. Bini, and J. V. Kamath, "Review on span-60 based non-ionic surfactant vesicles (niosomes) as novel drug delivery," *International Journal of Research in Pharmaceutical and Biomedical Sciences*, vol. 3, pp. 6–12, 2012.
- [16]. C. P. Jain and S. P. Vyas, "Preparation and characterization of niosomes containing rifampicin for lung targeting," *Journal of Microencapsulation*, vol. 12, no. 4, pp. 401–407, 1995.
- [17]. S. Mandal, C. Banerjee, S. Ghosh, J. Kuchlyan, and N. Sarkar, "Modulation of the photophysical properties of curcumin in nonionic surfactant (Tween-20) forming micelles and niosomes: a comparative study of different microenvironments," *The Journal of Physical Chemistry B*, vol. 117, no. 23, pp. 6957–6968, 2013.
- [18]. L. Di Marzio, C. Marianecchi, M. Petrone, F. Rinaldi, and M. Carafa, "Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20," *Colloids and Surfaces B: Biointerfaces*, vol. 82, no. 1, pp. 18–24, 2011.
- [19]. M. Imran, M. R. Shah, F. Ullah et al., "Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime," *International Journal of Pharmaceutics*, vol. 505, no. 1-2, pp. 122–132, 2016.
- [20]. M. Manconi, C. Sinico, D. Valenti, F. Lai, and A. M. Fadda, "Niosomes as carriers for tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin," *International Journal of Pharmaceutics*, vol. 311, no. 1-2, pp. 11–19, 2006.
- [21]. P. Bandyopadhyay and M. Johnson, "Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release," *Colloids and Surfaces B: Biointerfaces*, vol. 58, no. 1, pp. 68–71, 2007.
- [22]. Nangare K A, Powar S D, Kate V K, Nandgude T D, Payghan S A., Exploring the State-of-Art of Nanosuspensions: Theoretical Aspects, Formulation and Characterization. *Inventi:pndds/25746/18*.
- [23]. Nangare K. A., Powar S. D., Payghan S.A. Nanoengineered erythrovesicles: Camouflaged capecitabine as a biomimetic delivery platform. *Asian Journal of Pharmaceutics* Jan-Mar 2017 • 11 (1) | 53-64E-ISSN : 1998-409X.
- [24]. Nangare K. A., Powar S. D., Payghan S.A. Design of Three-factor response surface optimization of Camouflaged capecitabine Nanoerythrovesicles *Asian Journal of Pharmaceutics* Oct-Dec 2016; 10 (4), 306-321E-ISSN : 1998-409X.
- [25]. Nangare K. A., Powar S. D., Payghan S.A. Nanoerythrovesicles: Engineered erythrocytes as a novel carrier for the targeted drug delivery *Asian Journal of Pharmaceutics* Jul-Sep 2016 (Suppl) 10 (3), S223-S233E-ISSN : 1998-409X.
- [26]. Sarda Akash, Powar Sayali, Nangare Kavita, Payghan S A Formulation and Characterization of Sublingual Tablet for Rapid Absorption and Taste Masking of Tenoxicam *Inventi Rapid: Pharm Tech*, 2018(1):1-14, 2017.E-ISSN 0976-7576.
- [27]. Nangare K. A., Nangare K. A., Powar S. D., Kate V. K., Patwekar S. R. Payghan S. A Therapeutics applications of Nanosuspension in Topical/ Mucosal delivery drug *Delivery Research* 7(1):00170.10.15406/jnmr.2018.07.00170

- [28]. Nangare K.A., Kate V. K., Khavane.K K., Powar S. D.,Payghan S. A. Nanosuspension: Potential applications of Nano Therapeutics in Ocular DeliveryModern Applications of Bioequivalence & Bioavailability (MABB)2018; 3(2): 555608.
- [29]. Nangare K. A., Powar S. D., Kate V. K., Payghan S. A.Exploring the state-of-art of Nanosuspensions: Theoretical aspects, Formulation and CharacterizationJournal of Pharmaceutics and Drug Research.
- [30]. Monish Lad,Kavita Nangare,Aishwarya Patil,Rutika Harshad, Santosh Payghan, Renal Stone Disease: Genesis, Evoluation and Iatric Treatmement. International Journal of creative Research Thoughts, 2320-2882.